The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Antipsychotic Drugs: A Concise Review of History, Classification, Indications, Mechanism, Efficacy, Side Effects, Dosing, and Clinical Application
Abstract
The introduction of the first antipsychotic drug, chlorpromazine, was a milestone for psychiatry. The authors review the history, classification, indications, mechanism, efficacy, side effects, dosing, drug initiation, switching, and other practical issues and questions related to antipsychotics. Classifications such as first-generation/typical versus second-generation/atypical antipsychotics are neither valid nor useful; these agents should be described according to the Neuroscience-based Nomenclature (NbN). Antipsychotic drugs are not specific for treating schizophrenia. They reduce psychosis regardless of the underlying diagnosis, and they go beyond nonspecific sedation. All currently available antipsychotic drugs are dopamine blockers or dopamine partial agonists. In schizophrenia, effect sizes for relapse prevention are larger than for acute treatment. A major unresolved problem is the implausible increase in placebo response in antipsychotic drug trials over the decades. Differences in side effects, which can be objectively measured, such as weight gain, are less equivocal than differences in rating-scale-measured (subjective) efficacy. The criteria for choosing among antipsychotics are mainly pragmatic and include factors such as available formulations, metabolism, half-life, efficacy, and side effects in previous illness episodes. Plasma levels help to detect nonadherence, and once-daily dosing at night (which is possible with many antipsychotics) and long-acting injectable formulations are useful when adherence is a problem. Dose-response curves for both acute treatment and relapse prevention follow a hyperbolic pattern, with maximally efficacious average dosages for schizophrenia of around 5 mg/day risperidone equivalents. Computer apps facilitating the choice between drugs are available. Future drug development should include pharmacogenetics and focus on drugs for specific aspects of psychosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Insel, T., Cuthbert, B., Garvey, M., Heinssen, R., Pine, D. S., Quinn, K., Sanislow, C., & Wang, P. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09091379 · Cited by 7,067
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Self-citationSecond-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Self-citationHuhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P., Cipriani, A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31135-3 · Cited by 1,753
Self-citationAntipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Farde, L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820070032005 · Cited by 1,419
Robinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
International Consensus Study of Antipsychotic Dosing
Gardner, D. M., Murphy, A. L., O'Donnell, H., Centorrino, F., & Baldessarini, R. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09060802 · Cited by 1,301
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090
Pillinger, T., McCutcheon, R. A., Vano, L., Mizuno, Y., Arumuham, A., Hindley, G., Beck, K., Natesan, S., Efthimiou, O., Cipriani, A., et al. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30416-x · Cited by 1,090
Geddes, J., Freemantle, N., Harrison, P., & Bebbington, P. (2000) · BMJ · doi:10.1136/bmj.321.7273.1371 · Cited by 1,062
A History of Psychiatry: From the Era of the Asylum to the Age of Prozac.
Herman, E., & Shorter, E. (1997) · The Journal of American History · doi:10.2307/2953108 · Cited by 1,056
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,034
Self-citationHo, B.-C., Andreasen, N. C., Ziebell, S., Pierson, R., & Magnotta, V. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.199 · Cited by 971
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931
Self-citationDopamine receptors and the dopamine hypothesis of schizophrenia
Seeman, P. (1987) · Synapse · doi:10.1002/syn.890010203 · Cited by 880
Leucht, S., Pitschel-Walz, G., Abraham, D., & Kissling, W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00105-4 · Cited by 796
Self-citationLeucht, S., Wahlbeck, K., Hamann, J., & Kissling, W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13306-5 · Cited by 725
Self-citationTiihonen, J., Mittendorfer-Rutz, E., Majak, M., Mehtälä, J., Hoti, F., Jedenius, E., Enkusson, D., Leval, A., Sermon, J., Tanskanen, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1322 · Cited by 670
Zhou, Y., Ingelman‐Sundberg, M., & Lauschke, V. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.690 · Cited by 583
Diagnosis and Drug Treatment of Psychiatric Disorders
Klein, D. F. (1970) · The British Journal of Psychiatry · doi:10.1192/s0007125000193523 · Cited by 563
Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia
Shekhar, A., Potter, W. Z., Lightfoot, J., Lienemann, J., Dubé, S., Mallinckrodt, C., Bymaster, F. P., McKinzie, D. L., & Felder, C. C. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.06091591 · Cited by 560
Significance of Neuroleptic Dose and Plasma Level in the Pharmacological Treatment of Psychoses
Baldessarini, R. J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800250095013 · Cited by 545
Leucht, S., Leucht, C., Huhn, M., Chaimani, A., Mavridis, D., Helfer, B., Samara, M., Rabaioli, M., Bächer, S., Cipriani, A., et al. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16121358 · Cited by 542
Self-citationLeucht, S., Arbter, D., Engel, R. R., Kissling, W., & Davis, J. M. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002136 · Cited by 489
Amisulpride, an Unusual “Atypical” Antipsychotic: A Meta-Analysis of Randomized Controlled Trials
Leucht, S., Pitschel-Walz, G., Engel, R. R., & Kissling, W. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.180 · Cited by 470
Self-citationLeucht, S., Hierl, S., Kissling, W., Dold, M., & Davis, J. M. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.096594 · Cited by 451
Self-citationDorph-Petersen, K.-A., Pierri, J. N., Perel, J. M., Sun, Z., Sampson, A. R., & Lewis, D. A. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300710 · Cited by 437
McEvoy, J. P. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810320063009 · Cited by 381
Slee, A., Nazareth, I., Bondaronek, P., Liu, Y., Cheng, Z., & Freemantle, N. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31793-8 · Cited by 372
Kishimoto, T., Hagi, K., Kurokawa, S., Kane, J. M., & Correll, C. U. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00039-0 · Cited by 369
Dose Response and Dose Equivalence of Antipsychotics
Davis, J. M., & Chen, N. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000117422.05703.ae · Cited by 358
Self-citationAndreasen, N. C., Liu, D., Ziebell, S., Vora, A., & Ho, B.-C. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12050674 · Cited by 352
Shepherd, M., Watt, D., Falloon, I., & Smeeton, N. (1989) · Psychological Medicine. Monograph Supplement · doi:10.1017/s026418010000059x · Cited by 350
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia
Brannan, S. K., Sawchak, S., Miller, A. C., Lieberman, J. A., Paul, S. M., & Breier, A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2017015 · Cited by 340
Huhn, M., Tardy, M., Spineli, L. M., Kissling, W., Förstl, H., Pitschel-Walz, G., Leucht, C., Samara, M., Dold, M., Davis, J. M., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.112 · Cited by 333
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0037-1600991 · Cited by 325
Furukawa, T. A., Cipriani, A., Cowen, P. J., Leucht, S., Egger, M., & Salanti, G. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30217-2 · Cited by 322
Self-citationDose-response meta-analysis of antipsychotic drugs for acute schizophrenia
Leucht, S., Crippa, A., Siafis, S., Patel, M. X., Orsini, N., & Davis, J. M. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010034 · Cited by 301
Self-citationMoustgaard, H., Clayton, G. L., Jones, H. E., Boutron, I., Jørgensen, L., Laursen, D. R. T., Olsen, M. F., Paludan-Müller, A., Ravaud, P., Savović, J., et al. (2020) · BMJ · doi:10.1136/bmj.l6802 · Cited by 300
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477313 · Cited by 270
Samaha, A.-N., Seeman, P., Stewart, J., Rajabi, H., & Kapur, S. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5416-06.2007 · Cited by 262
Siskind, D., Orr, S., Sinha, S., Yu, O., Brijball, B., Warren, N., MacCabe, J. H., Smart, S. E., & Kisely, S. (2022) · The British Journal of Psychiatry · doi:10.1192/bjp.2021.61 · Cited by 255
Angermeyer, M. C., van der Auwera, S., Carta, M. G., & Schomerus, G. (2017) · World Psychiatry · doi:10.1002/wps.20383 · Cited by 253
Silverstone, P. H., Ravindran, A., & the Venlafaxine XR 360 Study Group (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0105 · Cited by 246
Scherk, H., Pajonk, F. G., & Leucht, S. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.4.442 · Cited by 243
Self-citationGalling, B., Roldán, A., Hagi, K., Rietschel, L., Walyzada, F., Zheng, W., Cao, X., Xiang, Y., Zink, M., Kane, J. M., et al. (2017) · World Psychiatry · doi:10.1002/wps.20387 · Cited by 239
Self-citationKrause, M., Zhu, Y., Huhn, M., Schneider-Thoma, J., Bighelli, I., Nikolakopoulou, A., & Leucht, S. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0869-3 · Cited by 230
Self-citationSchneider-Thoma, J., Chalkou, K., Dörries, C., Bighelli, I., Ceraso, A., Huhn, M., Siafis, S., Davis, J. M., Cipriani, A., Furukawa, T. A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01997-8 · Cited by 224
Self-citationMilosavljevic, F., Bukvic, N., Pavlovic, Z., Miljevic, C., Pešic, V., Molden, E., Ingelman-Sundberg, M., Leucht, S., & Jukic, M. M. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3643 · Cited by 218
Self-citationCarbon, M., Kane, J. M., Leucht, S., & Correll, C. U. (2018) · World Psychiatry · doi:10.1002/wps.20579 · Cited by 214
Volpi, S., Potkin, S. G., Malhotra, A. K., Licamele, L., & Lavedan, C. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04391 · Cited by 204
Takeuchi, H., Siu, C., Remington, G., Fervaha, G., Zipursky, R. B., Foussias, G., & Agid, O. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-018-0278-3 · Cited by 200
Tiihonen, J., Tanskanen, A., & Taipale, H. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17091001 · Cited by 196
Siafis, S., Çıray, O., Wu, H., Schneider‐Thoma, J., Bighelli, I., Krause, M., Rodolico, A., Ceraso, A., Deste, G., Huhn, M., et al. (2022) · Molecular Autism · doi:10.1186/s13229-022-00488-4 · Cited by 188
Self-citationZohar, J., Stahl, S., Moller, H.-J., Blier, P., Kupfer, D., Yamawaki, S., Uchida, H., Spedding, M., Goodwin, G. M., & Nutt, D. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.08.019 · Cited by 186
THE NORTHWICK PARK "FUNCTIONAL" PSYCHOSIS STUDY: DIAGNOSIS AND TREATMENT RESPONSE
Johnstone, E., Frith, C., Crow, T., & Owens, D. C. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90682-4 · Cited by 186
Schneider‐Thoma, J., Chalkou, K., Doerries, C., Bighelli, I., Ceraso, A., Huhn, M., Siafis, S., Davis, J. M., Cipriani, A., Furukawa, T. A., et al. (2022) · doi:10.48350/166230 · Cited by 180
Self-citationEuropean Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia
Vita, A., Gäebel, W., Mucci, A., Sachs, G., Barlati, S., Giordano, G. M., Nibbio, G., Nordentoft, M., Wykes, T., & Galderisi, S. (2022) · European Psychiatry · doi:10.1192/j.eurpsy.2022.2315 · Cited by 175
Schizophrenia—A Follow-up Study of Results of Treatment: II. Hospital Stay Over Two to Five Years
May, P. R. A. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770040047009 · Cited by 175
Grossberg, G. T., Kohegyi, E., Mergel, V., Josiassen, M. K., Meulien, D., Hobart, M., Slomkowski, M., Baker, R. A., McQuade, R. D., & Cummings, J. L. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.09.009 · Cited by 169
Kishi, T., Ikuta, T., Matsuda, Y., Sakuma, K., Okuya, M., Mishima, K., & Iwata, N. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00946-6 · Cited by 169
Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia
Paul, S. M., Yohn, S. E., Popiolek, M., Miller, A., & Felder, C. C. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.21101083 · Cited by 164
Siafis, S., Wu, H., Wang, D., Burschinski, A., Nomura, N., Takeuchi, H., Schneider-Thoma, J., Davis, J. M., & Leucht, S. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02203-y · Cited by 161
Self-citationDopamine D2 Receptor Occupancy and Clinical Effects: A Systematic Review and Pooled Analysis
Uchida, H., Takeuchi, H., Graff‐Guerrero, A., Suzuki, T., Watanabe, K., & Mamo, D. C. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182214aad · Cited by 161
A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab017 · Cited by 157
Meta-Regression Analysis of Placebo Response in Antipsychotic Trials, 1970–2010
Agid, O., SIU, C. O., Potkin, S. G., Kapur, S., Watsky, E. J., Vanderburg, D. G., Zipursky, R. B., & Remington, G. J. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12030315 · Cited by 155
Bugarski‐Kirola, D., Blaettler, T., Arango, C., Fleischhacker, W., Garibaldi, G. M., Wang, A., Dixon, M., Bressan, R. A., Nasrallah, H. A., Lawrie, S. M., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.11.014 · Cited by 154
Taipale, H., Mehtälä, J., Tanskanen, A., & Tiihonen, J. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx176 · Cited by 153
Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials
Wu, H., Siafis, S., Hamza, T., Schneider‐Thoma, J., Davis, J. M., Salanti, G., & Leucht, S. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac001 · Cited by 151
Self-citationOstuzzi, G., Bertolini, F., Tedeschi, F., Vita, G., Brambilla, P., Fabro, L. D., Gastaldon, C., Papola, D., Purgato, M., Nosari, G., et al. (2022) · World Psychiatry · doi:10.1002/wps.20972 · Cited by 148
Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice
Schoretsanitis, G., Kane, J. M., Correll, C. U., et al. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19cs13169 · Cited by 148
Zhu, Y., Li, C., Huhn, M., Rothe, P., Krause, M., Bighelli, I., Schneider‐Thoma, J., & Leucht, S. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.06.011 · Cited by 147
Self-citationStauffer, V. L., Millen, B. A., Andersen, S. W., Kinon, B. J., LaGrandeur, L., Lindenmayer, J., & Gomez, J. C. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.08.020 · Cited by 140
Downing, A. M., Kinon, B. J., Millen, B. A., Zhang, L., Liu, L., Ma, M., Brenner, R., Rayle, T. J., Nisenbaum, L., Zhao, F., et al. (2014) · BMC Psychiatry · doi:10.1186/s12888-014-0351-3 · Cited by 139
Zhu, Y., Krause, M., Huhn, M., Rothe, P., Schneider‐Thoma, J., Chaimani, A., Li, C., Davis, J. M., & Leucht, S. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30270-5 · Cited by 136
Self-citationTaipale, H., Schneider-Thoma, J., Pinzón-Espinosa, J., Radua, J., Efthimiou, O., Vinkers, C. H., Mittendorfer-Rutz, E., Cardoner, N., Pintor, L., Tanskanen, A., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.3990 · Cited by 129
Self-citationBurschinski, A., Schneider‐Thoma, J., Chiocchia, V., Schestag, K., Wang, D., Siafis, S., Bighelli, I., Wu, H., Hansen, W., Priller, J., et al. (2023) · World Psychiatry · doi:10.1002/wps.21036 · Cited by 125
Self-citationKritische Stellungnahme zum Begriff der Neuroleptika
Stille, G., & Hippius, H. (1971) · Pharmacopsychiatry · doi:10.1055/s-0028-1094311 · Cited by 124
Treatment of Schizophrenia: A Comparative Study of Five Treatment Methods.
Langner, H. P. (1969) · Archives of General Psychiatry · doi:10.1001/archpsyc.1969.01740160108017 · Cited by 114
Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia
Emsley, R., Nuamah, I., Hough, D., & Gopal, S. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.02.030 · Cited by 110
Leucht, S., Bauer, S., Siafis, S., Hamza, T., Wu, H., Schneider‐Thoma, J., Salanti, G., & Davis, J. M. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.2130 · Cited by 110
Self-citationMoncrieff, J., Crellin, N. E., Stansfeld, J. L., Cooper, R. E., Marston, L., Freemantle, N., Lewis, G., Hunter, R. M., Johnson, S., Barnes, T. R. E., et al. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00258-4 · Cited by 110
Bugarski‐Kirola, D., Iwata, N., Sameljak, S., Reid, C., Blaettler, T., Millar, L., Marques, T. R., Garibaldi, G. M., & Kapur, S. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30344-3 · Cited by 108
Yildiz, A., Siafis, S., Mavridis, D., Vieta, E., & Leucht, S. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00199-2 · Cited by 104
Self-citationAntipsychotic plasma levels in the assessment of poor treatment response in schizophrenia
McCutcheon, R. A., Beck, K., D’Ambrosio, E., Donocik, J. G., Gobjila, C., Jauhar, S., Kaar, S. J., Pillinger, T., Marques, T. R., Rogdaki, M., et al. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12825 · Cited by 103
Fink, M., Klein, D. F., & Kramer, J. C. (1965) · Psychopharmacology · doi:10.1007/bf00404162 · Cited by 87
Comparison of Treatment Response in Second-Episode Versus First-Episode Schizophrenia
Emsley, R. A., Oosthuizen, P., Koen, L., Niehaus, D. J. H., & Martínez, L. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31827bfcc1 · Cited by 84
Pietźcker, A., Gäebel, W., Köpcke, W., Linden, M., Müller, P., Müller-Spahn, F., & Tegeler, J. (1993) · Journal of Psychiatric Research · doi:10.1016/0022-3956(93)90059-b · Cited by 83
Determinants of Antipsychotic Response in Schizophrenia
Rabinowitz, J., Werbeloff, N., Caers, I., Mandel, F. S., Stauffer, V. L., Ménard, F., Kinon, B. J., & Kapur, S. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08853 · Cited by 81
Leucht, S., Schneider‐Thoma, J., Burschinski, A., Peter, N., Wang, D., Dong, S., Huhn, M., Nikolakopoulou, A., Salanti, G., & Davis, J. M. (2023) · World Psychiatry · doi:10.1002/wps.21089 · Cited by 78
Self-citationData-Driven Taxonomy for Antipsychotic Medication: A New Classification System
McCutcheon, R. A., Harrison, P. J., Howes, O. D., McGuire, P. K., Taylor, D. M., & Pillinger, T. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.04.004 · Cited by 76
Risperidone Maintenance Treatment in Schizophrenia: A Randomized, Controlled Trial
Wang, C., Xiang, Y., Cai, Z., Weng, Y., Bo, Q., Zhao, J., Liu, T., Wang, G., Weng, S.-M., Zhang, H., et al. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030358 · Cited by 70
Dong, S., Schneider-Thoma, J., Bighelli, I., Siafis, S., Wang, D., Burschinski, A., Schestag, K., Samara, M., & Leucht, S. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01654-2 · Cited by 68
Self-citationA Multidose Study of Haloperidol Decanoate in the Maintenance Treatment of Schizophrenia
Kane, J. M., Davis, J. M., Schooler, N. R., Marder, S. R., Casey, D. E., Brauzer, B., Mintz, J., & Conley, R. R. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.4.554 · Cited by 67
Self-citationCeraso, A., Lin, J., Schneider‐Thoma, J., Siafis, S., Heres, S., Kissling, W., Davis, J. M., & Leucht, S. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac041 · Cited by 65
Self-citationGuinart, D., Taipale, H. T., Rubio, J. M., Tanskanen, A. J., Correll, C. U., Tiihonen, J., & Kane, J. M. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab062 · Cited by 54
Wu, H., Siafis, S., Wang, D., Burschinski, A., Schneider‐Thoma, J., Priller, J., Davis, J. M., & Leucht, S. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.03.015 · Cited by 53
Self-citationLeucht, S., Chaimani, A., Krause, M., Schneider‐Thoma, J., Wang, D., Dong, S., Samara, M. T., Peter, N. L., Huhn, M., Priller, J., et al. (2022) · The Lancet Psychiatry · doi:10.1016/s2215-0366(22)00304-2 · Cited by 51
Self-citationHarcourt, B. E. (2011) · The Journal of Legal Studies · doi:10.1086/658404 · Cited by 48
Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study
Rubio, J. M., Taipale, H., Correll, C. U., Tanskanen, A., Kane, J. M., & Tiihonen, J. (2020) · Psychological Medicine · doi:10.1017/s0033291719001296 · Cited by 45
Employment Characteristics of Discharged Schizophrenics
Cole, N. J. (1964) · Archives of General Psychiatry · doi:10.1001/archpsyc.1964.01720210096015 · Cited by 45
Leucht, S., Chaimani, A., Leucht, C., Huhn, M., Mavridis, D., Helfer, B., Samara, M. T., Cipriani, A., Geddes, J. R., Salanti, G., et al. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.05.009 · Cited by 45
Self-citationStorosum, B. W. C., Mattila, T., Wohlfarth, T. D., Wied, C. C. G., Roes, K. C. B., van den Brink, W., de Haan, L., Denys, D. A. J. P., & Zantvoord, J. B. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114997 · Cited by 45
Leucht, S., Chaimani, A., Mavridis, D., Leucht, C., Huhn, M., Helfer, B., Samara, M. T., Cipriani, A., Geddes, J. R., & Davis, J. M. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0440-6 · Cited by 40
Self-citationSamara, M. T., Cao, H., Helfer, B., Davis, J. M., & Leucht, S. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.03.012 · Cited by 38
Self-citationEmsley, R. A., Nuamah, I. F., Gopal, S., Hough, D. W., & Fleischhacker, W. W. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17m11874 · Cited by 37
Adverse events after antipsychotic discontinuation: an individual participant data meta-analysis
Brandt, L., Schneider‐Thoma, J., Siafis, S., Efthimiou, O., Bermpohl, F., Loncar, L., Neumann, K., Hasan, A., Heinz, A., Leucht, S., et al. (2022) · The Lancet Psychiatry · doi:10.1016/s2215-0366(22)00014-1 · Cited by 35
Self-citationBitter, I., Katona, L., Zámbori, J., Takács, P., Fehér, L., Diels, J., Bacskai, M., Láng, Z., Gyáni, G., & Czobor, P. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.02.003 · Cited by 34
Second International Consensus Study of Antipsychotic Dosing (ICSAD-2)
McAdam, M., Baldessarini, R. J., Murphy, A. L., & Gardner, D. M. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231205688 · Cited by 34
Psychosis as a disorder of muscarinic signalling: psychopathology and pharmacology
McCutcheon, R. A., Weber, L. A. E., Nour, M. M., Cragg, S. J., & McGuire, P. K. (2024) · The Lancet Psychiatry · doi:10.1016/s2215-0366(24)00100-7 · Cited by 31
Henri Laborit and the inhibition of action
Kunz, E. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.1/ekunz · Cited by 30
Maiti, R., Mishra, A., Srinivasan, A., & Mishra, B. R. (2023) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13568 · Cited by 26
Adverse events after antipsychotic discontinuation: an individual participant data meta-analysis.
Brandt, L., Schneider‐Thoma, J., Siafis, S., Efthimiou, O., Bermpohl, F., Loncar, L., Neumann, K., Hasan, A., Heinz, A., Leucht, S., et al. (2022) · doi:10.48350/165893 · Cited by 24
Self-citationSiafis, S., Chiocchia, V., Macleod, M. R., Austin, C., Homiar, A., Tinsdeall, F., Friedrich, C., Ramage, F., Kennett, J., Nomura, N., et al. (2024) · Wellcome Open Research · doi:10.12688/wellcomeopenres.21302.1 · Cited by 24
Self-citationRapid vs. slow antipsychotic initiation in schizophrenia: A systematic review and meta-analysis
Takeuchi, H., Thiyanavadivel, S., Agid, O., & Remington, G. J. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.08.012 · Cited by 20
How antipsychotics impact the different dimensions of Schizophrenia: A test of competing hypotheses
Marques, T. R., Levine, S. Z., Reichenberg, A., Kahn, R. S., Derks, E. M., Fleischhacker, W., Rabinowitz, J., & Kapur, S. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.04.001 · Cited by 18
Which first-generation antipsychotics should be “repurposed” for the treatment of schizophrenia
Leucht, S., & Davis, J. M. (2022) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01378-1 · Cited by 18
Self-citationLeucht, S., Siafis, S., Rodolico, A., Peter, N. L., Müller, K., Waibel, J., Strube, W., Hasan, A., Bauer, I. O. B., Brieger, P., et al. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01712-9 · Cited by 18
Self-citationCorrell, C. U., Tocco, M., Hsu, J., GOLDMAN, R. S., & Pikalov, A. (2022) · European Psychiatry · doi:10.1192/j.eurpsy.2022.11 · Cited by 16
Kane, J. M., Schoretsanitis, G., Rubio, J. M., & Correll, C. U. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.01.035 · Cited by 16
Siafis, S., Bursch, N., Müller, K., Schmid, L., Schuster, F., Waibel, J., Huynh, T., Matthes, F., Rodolico, A., Brieger, P., et al. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04036-5 · Cited by 15
Self-citationSiafis, S., Deste, G., Ceraso, A., Mussoni, C., Vita, A., Hasanagić, S., Schneider‐Thoma, J., Papazisis, G., Davis, J. M., & Leucht, S. (2019) · Psychological Medicine · doi:10.1017/s003329171900285x · Cited by 14
Self-citationLeucht, S., Huhn, M., & Davis, J. M. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01335-y · Cited by 14
Self-citationHe, F., Luo, J., Huang, Y., Hao, Y., Sun, L., Ke, X., Wu, B., Chen, Y., Han, Y., Zhang, Y., et al. (2024) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/s13034-024-00764-6 · Cited by 14
Siafis, S., McCutcheon, R. A., Chiocchia, V., Ostinelli, E. G., Wright, S. L., Stansfield, C., Juma, D. O., Mantas, I., Howes, O. D., Rutigliano, G., et al. (2023) · Wellcome Open Research · doi:10.12688/wellcomeopenres.19866.1 · Cited by 11
Self-citationTajika, A., Furukawa, T. A., Shinohara, K., et al. (2023) · BMJ Mental Health · doi:10.1136/bmjment-2023-300654 · Cited by 11
Self-citationBenefits and harms of antipsychotic drugs in drug-naïve patients with psychosis: A systematic review
Danborg, P. B., & Gøtzsche, P. C. (2019) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-195063 · Cited by 10
Dong, S., Schneider‐Thoma, J., Siafis, S., Peter, N. L., & Leucht, S. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.04.007 · Cited by 7
Self-citationLeucht, S., Siafis, S., Schneider‐Thoma, J., Tajika, A., Priller, J., Davis, J. M., & Furukawa, T. A. (2024) · Schizophrenia · doi:10.1038/s41537-024-00442-8 · Cited by 3
Self-citation
Research works printed but not linked: 14
- Laborit H, 1952, Presse Med (1893), 60, 206
- Davis JM, 1985, J Clin Psychiatry, 46, 18
- Haase HJ, 1954, Der Nervenarzt, 25, 486
- Haase HJ, 1983, Der Neuroleptika Dosierung Ein Leitfaden für Klinik und Praxis unter besonderer Berücksichtigung psychotisch Kranker
- Abraham D, 1996, Psychiatr Prax, 23, 109
- Komossa K, 2010, Cochrane Database Syst Rev, 12, CD008121
- Meltzer HY, 1989, Psychopharmacol Bull, 25, 390
- Schoemaker H, 1997, J Pharmacol Exp Ther, 280, 83
- Wu H, 2024, Cochrane Database Syst Rev, 2, CD015665
- Smith RC, 1975, Psychopharmacol Commun, 1, 285
- Sampson S, 2013, Cochrane Database Syst Rev, 7, CD006196
- World Health Organization, 2023, WHO Model List of Essential Medicines: 23rd List, 2023
- Feber L, JAMA Psychiatry
- Foucault M, 1961, Folie et déraison: Histoire de la folie à l’âge classique
Cited by
Leucht, S., Siafis, S., McGrath, J. J., McGorry, P. D., Howes, O. D., Tamminga, C. A., Carr, R., Bighelli, I., Schneider‐Thoma, J., Priller, J., et al. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00667-6 · Cited by 81
Self-citationBiso, L., Carli, M., Scarselli, M., & Longoni, B. (2025) · Biomedicines · doi:10.3390/biomedicines13010085 · Cited by 22
“Antipsychotics are also indicated for the treatment of mood disorders, and they are used for different conditions and in various populations (including the pediatric and the elderly populations), both in approved and off-label settings [3–7].”
Zhao, G., Sun, Y., Zhang, Y., Lu, T., Lu, Z., Kang, Z., Schneider‐Thoma, J., Xie, W., Yang, Y., Guo, J., et al. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20250111 · Cited by 20
Self-citationPriming the Liver Endocytic Pathway to Accelerate Hepatobiliary Clearance of Nanoparticles
Ren, Y., Mei, F., Lu, H., Liang, Y., Zheng, R., Wang, Z., Liang, F., Du, B., & Jiang, X. (2026) · ACS Nano · doi:10.1021/acsnano.5c20532 · Cited by 12
IUPHAR review – Novel therapeutic targets for schizophrenia treatment: A translational perspective
Begni, V., Marchesin, A., & Riva, M. A. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107690 · Cited by 14
Metadata
- Authors
- Leucht, S., Priller, J., & Davis, J. M.
- Affiliations
- TUM Klinikum (DE)
- Venue
- American Journal of Psychiatry
- Published
- 2024-10-01
- Volume
- 181
- Issue
- 10
- Pages
- 865-878
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W4403006239
- Cited by
- 117
- References
- 133
- Citations by year
- 2026: 65 · 2025: 50 · 2024: 2
- FWCI
- 9.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- DZNE Pub (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- antipsychotic drugs, chlorpromazine, typical antipsychotics, atypical antipsychotics, dopamine antagonists, partial dopamine agonist, schizophrenia, psychosis, relapse prevention, placebo response, antipsychotic adverse effects, weight gain, medication adherence, long-acting injectable antipsychotics, once-daily dosing, dose-response relationship, pharmacogenetics, antipsychotic selection
- MeSH terms
- Humans, Schizophrenia, Antipsychotic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.